IN BRIEF: PureTech Health to start trials for anxiety, depression drug

PureTech Health PLC - clinical-stage biotherapeutics company - Says it will advance LYT-300 for ...

Alliance News 14 February, 2023 | 1:27PM
Email Form Facebook Twitter LinkedIn RSS

PureTech Health PLC - clinical-stage biotherapeutics company - Says it will advance LYT-300 for the potential treatment of anxiety disorders and post-partum depression. A placebo-controlled, phase 2a, proof-of-concept, social anxiety clinical trial is expected to begin in the first half of 2023. Results are expected by the end of the year. An open-label, phase 2a, proof-of-concept clinical trial in women with post-partum depression is expected to begin in the second half of 2023.

Current stock price: 233.50 pence, down 1.7% in London on Tuesday afternoon

12-month change: down 15%

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
PureTech Health PLC 220.00 GBX -0.90 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures